Buy or sell Exicure stock pre IPO via an EquityZen fund
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
About Exicure Stock
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
David A. Giljohann
Chad A. Mirkin
C. Shad Thaxton
Director Program Management